Aditx Therapeutics’ $9.6 Million Underwritten Public Offering

Ambrogio Visconti

Sheppard Mullin advised Aditx Therapeutics, Inc. on the deal. Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

…

This content is for Standard 1 Year members only.
Login Join Now